Humacyte Enterprise Value Over E B I T D A from 2010 to 2024
| HUMAW Stock | USD 1.85 0.02 1.09% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (2.81) | Current Value (2.67) | Quarterly Volatility 12.44061686 |
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
Humacyte | Enterprise Value Over E B I T D A |
Latest Humacyte's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Humacyte over the last few years. It is Humacyte's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Humacyte Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 1.41 | |
| Geometric Mean | 2.19 | |
| Coefficient Of Variation | 882.76 | |
| Mean Deviation | 5.99 | |
| Median | (1.60) | |
| Standard Deviation | 12.44 | |
| Sample Variance | 154.77 | |
| Range | 49.1693 | |
| R-Value | 0.29 | |
| Mean Square Error | 152.95 | |
| R-Squared | 0.08 | |
| Significance | 0.30 | |
| Slope | 0.80 | |
| Total Sum of Squares | 2,167 |
Humacyte Enterprise Value Over E B I T D A History
About Humacyte Financial Statements
Humacyte investors use historical fundamental indicators, such as Humacyte's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (2.81) | (2.67) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.